A 4-week vancomycin pulse and taper regimen may be a safe and effective strategy to delay or prevent Clostridioides difficile ...
Research found fecal microbiota transplantation (FMT) to be an optimal cost-effective treatment strategy for first and subsequent recurrent Clostridioides difficile infection (CDI), challenging ...
Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta's lead program, VE303, is ...
A 16% lower adjusted risk in recurrent Clostridioides difficile infections was found in 2018 compared with 2013 across diverse US sites part of the CDC’s Emerging Infections Program. Risk of recurrent ...
Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...
A vancomycin pulse and taper regimen was superior to a standard pulse regimen for the prevention of recurrent CDI.
Treatment with ridinilazone was found to significantly decrease the rate of recurrent Clostridioides difficile infection (CDI) compared with vancomycin. Treatment with ridinilazone was found to ...
REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff ...
WASHINGTON -- Extended follow-up of a phase III trial demonstrated continued benefit for an investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infections.
Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta's lead program, VE303, is ...
BOULDER, Colo., March 09, 2026--(BUSINESS WIRE)--Crestone, Inc. ("Crestone") today announced recent publication in the leading infectious disease journal, The Lancet Infectious Diseases, of positive ...
I read your recent column about a person who was refusing antibiotics due to a fear of a Clostridioides difficile (C. diff) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results